Hepatitis in patients with acute nonlymphocytic leukemia

The American Journal of Medicine
J C WadeJ H Hoofnagle

Abstract

Three consecutive groups (University of Maryland Cancer Center protocols 7110, 7405, and 7802) of patients with acute nonlymphocytic leukemia who achieved a complete hematologic remission with similar antileukemic therapy were reviewed for the development of hepatitis. Ninety-four (73 percent) experienced viral hepatitis; eight had type B hepatitis and 86 had non-A/non-B hepatitis. The hepatitis was mild in all patients. Hepatitis secondary to cytomegalovirus, herpes simplex virus, Epstein-Barr virus, or Toxoplasma gondii was not observed. Antibody to type A hepatitis was common, but acute infection could not be substantiated. All cases of type B hepatitis in which the surface antigen could be serotyped were found to have the less frequently observed ayw marker, suggesting a common donor as the source of infection. The median duration of complete remission was longer (p = 0.03) for patients in Group II (protocol 7405) who contracted hepatitis (247 days) compared with patients without hepatitis (125 days). Median overall survival was also longer (p = 0.01) for these patients in whom hepatitis developed (672 days versus 372 days, respectively). No prolongation of complete remission duration or survival could be demonstrated for p...Continue Reading

References

Nov 1, 1979·Transfusion·E Tabor, R J Gerety
Apr 10, 1975·The New England Journal of Medicine·S M FeinstoneP V Holland
Sep 1, 1975·Postgraduate Medicine·D J Gocke
Sep 30, 1976·The New England Journal of Medicine·W SzmunessD C Wong
Jul 1, 1977·Annals of Internal Medicine·J H HoofnagleR H Purcell
Feb 1, 1979·Annals of Internal Medicine·J C Barton, M E Conrad
Jul 1, 1979·Annals of Internal Medicine·M BermanE A Jones
Jun 22, 1978·The New England Journal of Medicine·J H HoofnagleH J Zimmerman
Jan 18, 1979·The New England Journal of Medicine·S KrugmanF Deinhardt
Sep 1, 1975·The American Journal of the Medical Sciences·H J AlterR H Purcell
Sep 1, 1975·The American Journal of the Medical Sciences·M GoldfieldW Pizzuti
Dec 26, 1974·The New England Journal of Medicine·J R WandsC C Carpenter
Apr 1, 1980·Annals of Internal Medicine·R D Aach, R A Kahn

❮ Previous
Next ❯

Citations

Aug 14, 1998·Environmental Health Perspectives·M T Smith, L Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.